Fundraising Activities - In April 2023, a total of 28 fundraising activities were reported, indicating a vibrant investment environment [3] - The "Lilly Asia VI Fund" has been established, becoming the largest market-oriented fundraising biopharmaceutical VC fund in recent years, with a total commitment exceeding RMB 40 billion [5] - Prologis launched its first data center income fund, raising approximately RMB 2.6 billion, marking a significant entry into the data center investment space [7] - The "Kaihui Future Fund" was established in collaboration with L'Oréal and the Shanghai Jing'an District government, focusing on the evolving beauty market in China [8] - A fund initiated by Anhui entrepreneurs raised RMB 3 billion to invest in local science and technology enterprises [10] - Blackstone's latest European real estate fund raised €9.8 billion (approximately $10.6 billion), setting a record for third-party capital commitments in Europe [11] - The "Sanofi-Kaihui Pharmaceutical Innovation Fund" was established with a management scale of approximately RMB 2 billion, focusing on clinical-stage innovative drug pipelines [14] - The "Hubei Highway Development Fund" was launched with a total scale of RMB 30 billion, aimed at supporting modern transportation systems [16] - The Shanghai Biopharmaceutical M&A Fund completed its first closing with a scale of RMB 5 billion, supporting the high-quality development of the biopharmaceutical industry [18] - Eurazeo Capital V successfully raised approximately €3 billion, focusing on high-growth sectors such as technology-enabled business services and healthcare [20] New Fund Establishments - The "Zero One Venture" announced the completion of a new RMB 500 million fund, focusing on intelligent manufacturing and cross-border ventures [22] - The "Hongyi Investment" established a fund in Yixing with a first closing amount of RMB 606 million, targeting new energy and new materials [24] - The "Shaanxi Financial and High-tech Investment Fund" completed its second closing, focusing on semiconductor and AI sectors with a total scale of RMB 1.198 billion [26] - The "Pudong Venture Capital Fund" was launched with a target scale of RMB 1 billion, focusing on the biopharmaceutical industry [28] - Wuxi announced a market-oriented AI industry fund with a total scale of RMB 1 billion to support AI development [30] - The "Changfei Angel Fund" was launched with a total scale of RMB 600 million, focusing on optoelectronic information and AI sectors [32] - The "Low-altitude Economy Fund" in Sichuan was established to invest in eVTOL manufacturing, marking the province's first fund in this area [34] - The "Fangxi Purple Peak Venture Capital Fund" was registered, focusing on technology transfer and innovation in Hefei [36] - The "Yaan Chuan Business Emerging Industry Fund" was established with a registered scale of RMB 100 million, targeting seed and angel investments [39] - The "Wuhan University of Technology Innovation Fund" was launched with an initial fundraising scale of RMB 1 billion [41] Strategic Collaborations - The "AI Angel Fund" was launched by Shanghai Jiao Tong University, focusing on early-stage AI startups with a total scale of RMB 300 million [42] - The "Conch Private Equity Fund" was established, focusing on strategic emerging industries such as new materials and renewable energy [44] - The "Nongyin AIC Fund" was established in Tianjin, focusing on new generation information technology and intelligent manufacturing [56] - The "Hunan Gongrong Dici Venture Capital Fund" was registered, marking the first AIC venture capital fund in Hunan with a scale of RMB 1 billion [58] - The "Qingdao AIC Equity Investment Fund" was established, marking the first AIC fund in the city, with a focus on various strategic emerging industries [60]

对接需求请扫码 每日｜荐读 | 活动： 「2025中国产业资本峰会」圆满落幕，CVC成为投资行业枢纽！ | | --- | | 榜单： 「2025产业投资100强」正式发布 | | 报告： 独角兽的"新双轮驱动"：《2025中国CVC影响力报告》发布 | | 报告： 哪些LP在活跃出资？——《LP全景报告2024》发布 | 据悉，中生引领基金是引领区产业发展基金发起设立的又一支产业基金，目标总规模10亿元，首 关规模5亿元，由浦东创投集团旗下浦东资本担任基金管理人，首关出资人包括浦东创投集团、中 国生物制药、孚腾资本、杭州科百特。基金成立后将聚焦服务生物医药产业，精准高效解决生物医 药产业"融资难、周期长、风险高"痛点，推动生物医药产业向高端化、国际化、集群化方向发展。 按照投资策略，中生引领基金聚焦成长期创新型生物医药企业开展投资，赋能企业在研发、生产、 销售等全流程环节。未来，浦东创投集团与中国生物制药将重点以市场化方式整合优质要素资源， 培育一批具有全球竞争力的领军企业，推动生物医药产业高质量发展，为浦东现代化产业体系建设 注入新动能。 来源：浦东发布 4月22日上午，中生引领（上海）私募投资基金（以下 ...